Synapse
⌘+K
Sign In
Sign Up for Free
Synapse
Sign In
Sign Up for Free
Home
Communities
Explore
More
Language
English
English
Ambrx (United States)
h-index: 26
Total citations: 3,209
Total papers: 74
Homepage:
http://ambrx.com/
Recent papers from Ambrx (United States)
Porcine interferon-alpha but not interferon-lambda inhibits replication of genotypically diverse PRRSV isolates in vitro
Frontiers in Veterinary Science · 2026
AI-SCM CMM: A Capability Maturity Model for Artificial Intelligence Integration in Supply Chain Management.
2026
AI-SCM CMM: A Capability Maturity Model for Artificial Intelligence Integration in Supply Chain Management.
2026
Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial
Clinical Cancer Research · 2026
Preclinical Characterization of ARX517, a Site-specific Stable PSMA-Targeted Antibody Drug Conjugate for Treatment of Metastatic Castration-Resistant Prostate Cancer
Molecular Cancer Therapeutics · 2024
ACE-BREAST-03: A phase 2 trial evaluating ARX788, an anti-HER2 antibody drug conjugate (ADC), for the treatment of HER2+ metastatic breast cancer (mBC) in patients who have been previously treated with trastuzumab deruxtecan (T-DXd).
Journal of Clinical Oncology · 2024
Abstract PO1-04-01: Phase 1 dose escalation study of ARX788, a next-generation anti-HER2 antibody drug conjugate, in heavily pretreated breast cancer patients
Cancer Research · 2024
Abstract PO1-04-02: ACE-Breast-03: A phase 2 study of ARX788, a novel next-generation anti-HER antibody-drug conjugate in HER2-positive metastatic breast cancer patients previously treated with trastuzumab deruxtecan
Cancer Research · 2024
Prophylactic treatment with PEGylated bovine IFNλ3 effectively bridges the gap in vaccine-induced immunity against FMD in cattle
Frontiers in Microbiology · 2024
Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types
Cancer Research · 2024
Recombinant Alpha-1 Antitrypsin–Fc Fusion Protein INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency: A Phase 1 Study
Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation · 2024
Preclinical Characterization and Phase I Trial Results of INBRX-109, A Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma
Clinical Cancer Research · 2023
Cancer detection in clinical practice and using blood-based liquid biopsy: A retrospective audit of over 350 dogs
Journal of Veterinary Internal Medicine · 2023
ARX788, a Site-specific Anti-HER2 Antibody–Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1–resistant Breast and Gastric Cancers
Molecular Cancer Therapeutics · 2020
Development of Anti-CD74 Antibody–Drug Conjugates to Target Glucocorticoids to Immune Cells
Bioconjugate Chemistry · 2018
Novel Phosphate Modified Cathepsin B Linkers: Improving Aqueous Solubility and Enhancing Payload Scope of ADCs
Bioconjugate Chemistry · 2016
Discovery of Pyrophosphate Diesters as Tunable, Soluble, and Bioorthogonal Linkers for Site-Specific Antibody–Drug Conjugates
Journal of the American Chemical Society · 2016
Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers
Angewandte Chemie International Edition · 2015
Multiformat T‐Cell‐Engaging Bispecific Antibodies Targeting Human Breast Cancers
Angewandte Chemie · 2015
Antibody Conjugates with Unnatural Amino Acids
Molecular Pharmaceutics · 2015